Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shifa PCSK9 autocatalytic processing inhibitor
- Development stage
- Preclinical
- Lead developer
- Shifa Biomedical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shifa Precision (a division of Shifa Biomedical) is developing a small molecule inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and the lowering of LDL cholesterol. This candidate, identified as Approach 2 in the company's pipeline, utilizes a novel mechanism of action by inhibiting the autocatalytic processing of PCSK9. PCSK9 is synthesized as a zymogen that must undergo intramolecular cleavage in the endoplasmic reticulum to become functional and be secreted. By blocking this maturation step, the compound prevents the production of functional PCSK9, thereby increasing the density of LDL receptors on the cell surface and enhancing the clearance of LDL-C from the blood. The program is currently in the preclinical stage of development.
- Other names
- PCSK9 Inhibitor (Approach 2)PCSK9 ModulatorPCSK-9 ModulatorPCSK 9 ModulatorShifa Precision-PCSK9-small molecule-Dyslipidemia-LDL-C loweringPCSK9 autocatalytic processing inhibitorPCSK-9 autocatalytic processing inhibitorPCSK 9 autocatalytic processing inhibitor
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on Shifa PCSK9 autocatalytic processing inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shifa PCSK9 autocatalytic processing inhibitor.